MA40075A - Combinaisons pour traiter des cancers - Google Patents
Combinaisons pour traiter des cancersInfo
- Publication number
- MA40075A MA40075A MA040075A MA40075A MA40075A MA 40075 A MA40075 A MA 40075A MA 040075 A MA040075 A MA 040075A MA 40075 A MA40075 A MA 40075A MA 40075 A MA40075 A MA 40075A
- Authority
- MA
- Morocco
- Prior art keywords
- cancer
- subject
- combinations
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des combinaisons pour traiter un cancer chez un sujet (par exemple, un humain) en ayant besoin, comprenant une quantité thérapeutiquement efficace d'un composé de formule (i) : ou un sel pharmaceutiquement acceptable de celui-ci, et un alcaloïde de pervenche, ou un sel pharmaceutiquement acceptable de celui-ci. Le sujet peut être à très haut risque ou à haut risque pour le cancer et peut ne pas répondre à un agent ou l'autre administré en monothérapie. Le sujet qui a le cancer peut également être réfractaire à au moins un traitement chimiothérapeutique, où est en récidive après traitement avec une chimiothérapie, ou les deux. Le cancer peut être une malignité hématologique, tel qu'une leucémie lymphome, ou un cancer à tumeur solide, tel que cancer pancréatique, du poumon et du colon.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462024424P | 2014-07-14 | 2014-07-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40075A true MA40075A (fr) | 2016-01-21 |
Family
ID=53762348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040075A MA40075A (fr) | 2014-07-14 | 2015-07-10 | Combinaisons pour traiter des cancers |
Country Status (16)
Country | Link |
---|---|
US (2) | US9707236B2 (fr) |
EP (1) | EP3169366A1 (fr) |
JP (1) | JP6310144B2 (fr) |
KR (1) | KR20170029580A (fr) |
CN (1) | CN106687139A (fr) |
AR (1) | AR103110A1 (fr) |
AU (1) | AU2015290000B2 (fr) |
BR (1) | BR112016028641A2 (fr) |
CA (1) | CA2955180A1 (fr) |
EA (1) | EA201790086A1 (fr) |
MA (1) | MA40075A (fr) |
MX (1) | MX2017000610A (fr) |
NZ (1) | NZ726365A (fr) |
SG (1) | SG11201610551TA (fr) |
TW (1) | TW201613589A (fr) |
WO (1) | WO2016010862A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5696052B2 (ja) | 2008-12-08 | 2015-04-08 | ギリアード コネチカット, インコーポレイテッド | イミダゾピラジンsyk阻害剤 |
PT2545052E (pt) | 2010-03-11 | 2015-02-18 | Gilead Connecticut Inc | Inibidores da syk à base de imidazopiridinas |
ES2822285T3 (es) | 2013-07-30 | 2021-04-30 | Kronos Bio Inc | Polimorfo de inhibidores de SYK |
ES2835549T3 (es) | 2013-12-04 | 2021-06-22 | Kronos Bio Inc | Métodos de tratamiento de cánceres |
TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
MA40075A (fr) | 2014-07-14 | 2016-01-21 | Gilead Sciences Inc | Combinaisons pour traiter des cancers |
CA3036384A1 (fr) | 2016-09-14 | 2018-03-22 | Gilead Sciences, Inc. | Inhibiteurs de syk |
KR102399996B1 (ko) | 2017-08-25 | 2022-05-20 | 길리애드 사이언시즈, 인코포레이티드 | Syk 억제제의 다형체 |
WO2020023921A1 (fr) * | 2018-07-27 | 2020-01-30 | Oregon Health & Science University | Traitements de mutations dans la leucémie aiguë myéloïde |
KR20210131372A (ko) | 2019-02-22 | 2021-11-02 | 크로노스 바이오, 인코포레이티드 | Syk 억제제로서의 축합된 피라진의 고체 형태 |
CN115768432A (zh) * | 2020-04-23 | 2023-03-07 | 南方研究院 | 使用4’-硫代-5-氮杂-2’-脱氧胞苷来治疗血癌的组合物及其用途 |
EP4185583A1 (fr) | 2020-07-23 | 2023-05-31 | Southern Research Institute | Polymorophes de 5-aza-4'-thio-2-désoxycytidine |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
FR2607813B1 (fr) | 1986-12-05 | 1989-03-31 | Montpellier I Universite | Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
US5137876A (en) | 1990-10-12 | 1992-08-11 | Merck & Co., Inc. | Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same |
DE4327027A1 (de) | 1993-02-15 | 1994-08-18 | Bayer Ag | Imidazoazine |
DE4337609A1 (de) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
DE4337611A1 (de) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln |
FR2711993B1 (fr) | 1993-11-05 | 1995-12-01 | Rhone Poulenc Rorer Sa | Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation. |
US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
WO1995026325A2 (fr) | 1994-03-25 | 1995-10-05 | Isotechnika Inc. | Potentialisation de medicaments par deuteration_______________ |
FR2723373B1 (fr) | 1994-08-02 | 1996-09-13 | Rhone Poulenc Rorer Sa | Forme purifiee de streptogramines, sa preparation et les compositions pharmaceutiques qui la contiennent |
AU5348396A (en) | 1995-05-01 | 1996-11-21 | Fujisawa Pharmaceutical Co., Ltd. | Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors |
US5593997A (en) | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
SE9704404D0 (sv) | 1997-11-28 | 1997-11-28 | Astra Ab | New compounds |
DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
JP2001302667A (ja) | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
EP1363702A4 (fr) | 2001-01-30 | 2007-08-22 | Cytopia Pty Ltd | Procedes d'inhibition de kinases |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
WO2002076985A1 (fr) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Composes utiles en tant qu'inhibiteurs de kinases pour le traitement des maladies hyperproliferatives |
AU2003219690A1 (en) | 2002-02-19 | 2003-09-09 | Pharmacia And Upjohn Company | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
CA2482991A1 (fr) | 2002-04-19 | 2003-10-30 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines, leur procede de production et leur utilisation |
US7312341B2 (en) | 2002-09-09 | 2007-12-25 | Cgi Pharmaceuticals, Inc. | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof |
US6992080B2 (en) | 2002-09-19 | 2006-01-31 | Schering Corporation | Imidazopyridines as cyclin dependent kinase inhibitors |
PE20050081A1 (es) | 2002-09-23 | 2005-03-01 | Schering Corp | Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas |
CA2499874A1 (fr) | 2002-09-23 | 2004-04-01 | Schering Corporation | Nouvelles imidazopyrazines comme inhibiteurs de kinases dependant des cyclines |
US7160885B2 (en) | 2003-02-10 | 2007-01-09 | Cgi Pharmaceuticals, Inc. | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity |
US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
US20060183746A1 (en) | 2003-06-04 | 2006-08-17 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
WO2005005429A1 (fr) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certaines imidazo[1,2-a]pyrazin-8-ylamines substituees heterocycliques et methodes d'inhibition de la tyrosine kinase de bruton utilisant ces composes |
US7259164B2 (en) | 2003-08-11 | 2007-08-21 | Cgi Pharmaceuticals, Inc. | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity |
US20050288295A1 (en) | 2003-11-11 | 2005-12-29 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
WO2005085252A1 (fr) | 2004-03-04 | 2005-09-15 | Biofocus Discovery Limited | Composes de 1,2-a' pyrazine imidazo interagissant avec les proteines kinases |
JP2008516973A (ja) | 2004-10-15 | 2008-05-22 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
EP1812442A2 (fr) | 2004-11-10 | 2007-08-01 | CGI Pharmaceuticals, Inc. | Certaines imidazo[1,2-a] pyrazin-8-ylamines et les procédés de fabrication et d'utilisation correspondants |
TWI337608B (en) | 2005-05-12 | 2011-02-21 | Abbott Lab | Apoptosis promoters |
KR20080074963A (ko) | 2005-11-10 | 2008-08-13 | 쉐링 코포레이션 | 단백질 키나제 억제제로서의 이미다조피라진 |
CA2662074A1 (fr) | 2006-08-30 | 2008-03-06 | Cellzome Limited | Derives de triazole en tant qu'inhibiteurs de kinase |
AR063581A1 (es) * | 2006-11-08 | 2009-02-04 | Schering Corp | Imidazopirazinas como inhibidores de proteina quinasa |
ES2462642T3 (es) | 2007-12-14 | 2014-05-26 | F. Hoffmann-La Roche Ag | Nuevos derivados de imidazo[1,2-a]piridina e imidazo[1,2-b]piridazina |
JP5496915B2 (ja) | 2008-02-13 | 2014-05-21 | シージーアイ ファーマシューティカルズ,インコーポレーテッド | 6−アリール−イミダゾ[1,2−a]ピラジン誘導体、その製造方法、及びその使用方法 |
EP2307413B1 (fr) | 2008-07-15 | 2015-09-09 | F. Hoffmann-La Roche AG | Nouvelles phényl-imidazopyridines et pyridazines |
TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶,其組合物及使用其之治療方法 |
JP5696052B2 (ja) | 2008-12-08 | 2015-04-08 | ギリアード コネチカット, インコーポレイテッド | イミダゾピラジンsyk阻害剤 |
US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
CN104744476B (zh) | 2008-12-08 | 2017-04-12 | 吉利德康涅狄格公司 | 咪唑并吡嗪syk抑制剂 |
US8362013B2 (en) | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
PT2545052E (pt) | 2010-03-11 | 2015-02-18 | Gilead Connecticut Inc | Inibidores da syk à base de imidazopiridinas |
LT2643322T (lt) | 2010-11-23 | 2018-01-10 | Abbvie Inc. | Apoptozę skatinančio agento druskos ir kristalinės formos |
WO2013188856A1 (fr) | 2012-06-14 | 2013-12-19 | Gilead Connecticut, Inc. | Inhibiteurs imidazopyrazine de la syk |
JP2015529195A (ja) | 2012-08-14 | 2015-10-05 | ギリアード カリストガ エルエルシー | 癌を処置するための組合せ治療 |
US20140148430A1 (en) | 2012-11-26 | 2014-05-29 | Gilead Connecticut, Inc. | Imidazopyridines syk inhibitors |
ES2822285T3 (es) | 2013-07-30 | 2021-04-30 | Kronos Bio Inc | Polimorfo de inhibidores de SYK |
AP2016009007A0 (en) | 2013-07-30 | 2016-01-31 | Gilead Connecticut Inc | Formulation of syk inhibitors |
AU2014296184B2 (en) | 2013-07-31 | 2017-04-27 | Gilead Sciences, Inc. | Syk inhibitors |
ES2835549T3 (es) * | 2013-12-04 | 2021-06-22 | Kronos Bio Inc | Métodos de tratamiento de cánceres |
TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
TW201617074A (zh) | 2014-07-14 | 2016-05-16 | 吉李德科學股份有限公司 | Syk(脾酪胺酸激酶)抑制劑 |
MA40075A (fr) | 2014-07-14 | 2016-01-21 | Gilead Sciences Inc | Combinaisons pour traiter des cancers |
TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
EP3285808A1 (fr) | 2015-04-21 | 2018-02-28 | Gilead Sciences, Inc. | Traitement de la maladie chronique du greffon contre l'hôte avec inhibiteurs syk |
-
2015
- 2015-07-10 MA MA040075A patent/MA40075A/fr unknown
- 2015-07-10 MX MX2017000610A patent/MX2017000610A/es unknown
- 2015-07-10 JP JP2017501698A patent/JP6310144B2/ja not_active Expired - Fee Related
- 2015-07-10 CA CA2955180A patent/CA2955180A1/fr not_active Abandoned
- 2015-07-10 KR KR1020177003609A patent/KR20170029580A/ko not_active Application Discontinuation
- 2015-07-10 AU AU2015290000A patent/AU2015290000B2/en not_active Ceased
- 2015-07-10 US US14/796,795 patent/US9707236B2/en active Active
- 2015-07-10 BR BR112016028641A patent/BR112016028641A2/pt not_active Application Discontinuation
- 2015-07-10 EP EP15744790.5A patent/EP3169366A1/fr not_active Withdrawn
- 2015-07-10 WO PCT/US2015/040029 patent/WO2016010862A1/fr active Application Filing
- 2015-07-10 CN CN201580038479.0A patent/CN106687139A/zh active Pending
- 2015-07-10 NZ NZ726365A patent/NZ726365A/en not_active IP Right Cessation
- 2015-07-10 EA EA201790086A patent/EA201790086A1/ru unknown
- 2015-07-10 SG SG11201610551TA patent/SG11201610551TA/en unknown
- 2015-07-13 AR ARP150102224A patent/AR103110A1/es unknown
- 2015-07-13 TW TW104122554A patent/TW201613589A/zh unknown
-
2017
- 2017-06-14 US US15/622,737 patent/US10080756B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2955180A1 (fr) | 2016-01-21 |
EA201790086A1 (ru) | 2017-07-31 |
TW201613589A (en) | 2016-04-16 |
KR20170029580A (ko) | 2017-03-15 |
US20180008608A1 (en) | 2018-01-11 |
US9707236B2 (en) | 2017-07-18 |
JP2017521442A (ja) | 2017-08-03 |
NZ726365A (en) | 2018-06-29 |
US10080756B2 (en) | 2018-09-25 |
SG11201610551TA (en) | 2017-01-27 |
US20160166579A1 (en) | 2016-06-16 |
BR112016028641A2 (pt) | 2017-08-22 |
AU2015290000A1 (en) | 2016-12-01 |
JP6310144B2 (ja) | 2018-04-18 |
AR103110A1 (es) | 2017-04-19 |
AU2015290000B2 (en) | 2018-05-17 |
MX2017000610A (es) | 2017-04-27 |
CN106687139A (zh) | 2017-05-17 |
EP3169366A1 (fr) | 2017-05-24 |
WO2016010862A1 (fr) | 2016-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ726365A (en) | Combinations for treating cancers | |
MX2016007311A (es) | Metodos para tratar canceres. | |
PH12016502354A1 (en) | Pharmaceutical composition | |
MX2021003389A (es) | Metodos para tratar el cancer. | |
MD4643B1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
EA201591924A1 (ru) | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 | |
MX2017015896A (es) | Agente anticancerigeno. | |
WO2019126739A8 (fr) | Thérapies anti-cancer à base de pamoate de pyrvinium | |
MX2022005298A (es) | Compuestos intermediarios de sintesis de inhibidores de a2a. | |
MX2018006531A (es) | Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada. | |
EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
MX2016002795A (es) | Compuestos de triazolona y usos de los mismos. | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
PH12020500665A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
PH12018502360A1 (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
WO2015038896A3 (fr) | Utilisation de wilforlide a pour surmonter la résistance à la chimiothérapie | |
PH12019500858A1 (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
MX2021002884A (es) | Terapia de combinacion para el tratamiento de cancer de prostata. | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
MX2018006776A (es) | Usos de pirimido-piridazinonas para tratar el cancer. | |
MX2016016842A (es) | Metodo para identificar y tratar lactantes prematuros en riesgo de displasia broncopulmonar. | |
NZ742470A (en) | Combination therapy for cancer | |
MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. | |
SG10201402352UA (en) | Therapeutic compositions for treating cancers | |
PH12021550815A1 (en) | New combination solution for treating chemotherapy refractory cancer |